Tune Therapeutics
Tune Therapeutics develops TEMPO, an epigenomic platform that fine-tunes gene activity without altering DNA. It is developing therapies for chronic hepatitis B, rare single-gene disorders and other conditions.
Facts
- HQ
- Seattle, Washington, USA and Durham, North Carolina, USA
- Sectors
- Biotechnology, Therapeutics, Epigenomics
- Stage
- Series B
- Members see funding amounts. .
Is this your organization? Claim it
Members see Tune Therapeutics's funding rounds, amounts and investors.
Seattle Flow is free for everyone.
- Claim and edit your profile
- Get alerts about you, your company, and anything else you care about
- Access the most comprehensive investor list in Seattle
- Join the conversation on news, podcasts, and events